Johns Hopkins University School of Medicine
We study how the genetic code governs messenger RNA fate—discovering that codon composition is a master determinant of transcript half-lives, with profound implications for gene regulation and therapeutics.
Our Research
Messenger RNA degradation plays a critical role in regulating transcript levels and is a major control point for modulating gene expression. A series of discoveries from our group have uncovered that a significant determinant for RNA degradation is the genetic code itself — a concept we call Codon Optimality.
We showed that mRNA decay rates are dictated by the percentage of codons deemed "optimal," based on the abundance of their cognate tRNAs relative to demand. Optimal codons are decoded rapidly by ribosomes, while non-optimal codons are read more slowly due to limiting tRNA concentration. The rate at which the ribosome decodes an mRNA ultimately determines transcript fate.
Most excitingly, the exact same mRNA sequence can differentially impact stability in distinct cell types — codon optimality is plastic and regulated from cell to cell. We leverage both yeast and mammalian systems to define the molecular interplay between the ribosome and the degradation complex.
Defining how the mRNA degradation machinery interacts with the ribosome, and how ribosome conformation signals transcript fate to the Ccr4-Not complex.
Translating fundamental discoveries into next-generation mRNA therapies — including poly(A)-tail mimetics and suppressor tRNAs for rare diseases like DMD and haploinsufficiency disorders.
Exploring how tissue-specific tRNA expression reprograms codon optimality, connecting tRNA metabolism to mRNA stability and neurodevelopmental disorders.
Investigating how chemical modifications to mRNA — including cytidine acetylation — alter codon optimality and tune translation efficiency across biological contexts.
Op-Eds & Public Engagement
An argument for reframing mRNA-CRISPR therapeutics as "molecular surgery" — precision interventions that deserve a regulatory pathway as bold as the science itself. Timed to the FDA Plausible Mechanism Framework comment period and the ASGCT Annual Meeting.
April 2026
Read in NYTmRNA platforms offer a decisive defensive advantage against engineered biological threats. Congress should restore research funding and the Pentagon should establish mRNA biodefense manufacturing as a strategic priority.
January 2026
Read the essayInvestment in U.S. mRNA vaccines collapsed 66% in a single year while other nations build the workforce, infrastructure, and regulatory frameworks to capture growth. Secretary Kennedy's ideological agenda is forfeiting the prize.
March 2026
Read the op-edCancer patients who received mRNA COVID-19 vaccines during treatment lived significantly longer — a finding that could open the door to more-effective cancer therapies with sustained federal investment.
November 2025
Read in WSJFederal funding for biomedical research pays off by enabling basic discoveries that lead to lifesaving treatments. Pulling back now risks squandering the most promising advances in a generation.
2025
Read in WSJInitiatives & Organizations
Co-founded the leading global advocacy coalition advancing mRNA technology through policy engagement, public education, and scientific communication. AMM unites industry, academia, and patient advocates across 30+ member organizations.
mrnamedicines.orgCo-founded the philanthropic arm dedicated to public education, combatting misinformation, and training the next generation of mRNA scientists and manufacturing professionals.
mrnafoundation.orgFounded and leading the Johns Hopkins–Mayo Clinic partnership developing mRNA-CRISPR therapeutics for rare diseases. Industry partners include Danaher, Aldevron, Acuitas Therapeutics, IDT, and Charles River Laboratories.
A Framework for HopeCo-founded the biotechnology company pioneering suppressor tRNA-based gene therapies for rare genetic diseases including Duchenne muscular dystrophy, cardiomyopathy, and developmental epileptic encephalopathies.
tevard.comProducing expert testimony, scientific rebuttals, and briefing materials opposing anti-mRNA legislation across multiple states, including Idaho, Tennessee, Louisiana, South Dakota, and South Carolina. Working with legislative strategy teams to protect mRNA innovation at the state and federal level.
Our Team
Bloomberg Distinguished Professor of RNA Biology & Therapeutics
Director, RNA Innovation Center
Johns Hopkins University School of Medicine & Whiting School of Engineering
A pioneering researcher in RNA biology, Dr. Coller has made fundamental contributions to our understanding of gene expression and mRNA stability. His groundbreaking work demonstrated that the genetic code is a major determinant of mRNA fate in eukaryotes, shifting paradigms in the field and opening new avenues for therapeutic development. He is co-founder of Tevard Biosciences and the Alliance for mRNA Medicines, and leads the REPAIRx consortium — a Johns Hopkins–Mayo Clinic partnership focused on mRNA-CRISPR therapeutics for rare diseases. An elected AAAS Fellow, he received his PhD in Cell and Molecular Biology from the University of Wisconsin-Madison and completed postdoctoral training at the Howard Hughes Medical Institute, University of Arizona.
Research Associate / Senior Scientist
BCMB PhD Student
MD/PhD Student
Postdoctoral Fellow
Postdoctoral Fellow
Graduate Student
Graduate Student
Graduate Student
Undergraduate
Managing Director
Laboratory Manager
Research Technologist
Complete Works
Resources
Our lab protocol book is freely available for download. It includes detailed procedures for RNA extraction, Northern blotting, mRNA stability assays, tRNA-seq, tethered function assays, and other methods developed in our lab over the past two decades.
Download Protocol Book ↓Get in Touch
AddressDepartment of Molecular Biology and Genetics
Johns Hopkins University
725 N. Wolfe St., PCTB 503
Baltimore, MD 21205-2105
Emailjmcoller [at] jhmi.edu
AffiliationsDepartment of Molecular Biology & Genetics
Department of Biomedical Engineering
Institute for NanoBioTechnology
RNA Innovation Center
Support Our Work
Your support fuels fundamental discoveries in RNA biology and accelerates the translation of basic science into life-changing therapies for rare diseases. Gifts of any size directly support graduate students, postdoctoral fellows, and the research infrastructure that makes breakthrough science possible.
Give Now →Donations support the Coller Lab and the RNA Innovation Center through the Johns Hopkins giving platform.
Donate Online